These studies shed light the therapeutic potential of targeting glutamine metabolism to regulate tumor growth and immune responses, indirectly supporting the hypothesis that modulating glutamine pathways may inhibit CRC metastasis by downregulating RAD23B. This evidence concerns the gene RAD23B and colorectal carcinoma.